Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.11.21 extracted from

  • Gleixner, K.V.; Ferenc, V.; Peter, B.; Gruze, A.; Meyer, R.A.; Hadzijusufovic, E.; Cerny-Reiterer, S.; Mayerhofer, M.; Pickl, W.F.; Sillaber, C.; Valent, P.
    Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536 (2010), Cancer Res., 70, 1513-1523.
    View publication on PubMed
Search for more literature for 2.7.11.21

Application

Application Comment Organism
medicine polo-like kinase may represent a novel drug target in imatinib-sensitive and imatinib-resistant chronic myeloid leukemia Homo sapiens

Inhibitors

Inhibitors Comment Organism Structure
BI 2536
-
 Homo sapiens
siRNA
-
 Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
ATP + a protein Homo sapiens
-
 ADP + a phosphoprotein
-
 ?

Organism

Organism UniProt Comment Textmining
Homo sapiens P53350
-
-

Posttranslational Modification

Posttranslational Modification Comment Organism
phosphoprotein
-
 Homo sapiens

Source Tissue

Source Tissue Comment Organism Textmining
chronic myeloid leukemia cell
-
 Homo sapiens
-
K-562 cell
-
 Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
ATP + a protein
-
 Homo sapiens ADP + a phosphoprotein
-
 ?

Synonyms

Synonyms Comment Organism
Plk1
-
 Homo sapiens
Polo-like kinase 1
-
 Homo sapiens

Cofactor

Cofactor Comment Organism Structure
ATP
-
 Homo sapiens

Expression

Organism Comment Expression
Homo sapiens inhibition of BCR/ABL by imatinib or nilotinib leads to decreased expression of PLK1 protein in CML cells down